Array ( [urn:ac.highwire.org:guest:identity] => Array ( [runtime-id] => urn:ac.highwire.org:guest:identity [type] => guest [service-id] => ajnr-ac.highwire.org [access-type] => Controlled [privilege] => Array ( [urn:ac.highwire.org:guest:privilege] => Array ( [runtime-id] => urn:ac.highwire.org:guest:privilege [type] => privilege-set [privilege-set] => GUEST ) ) [credentials] => Array ( [method] => guest ) ) ) 1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 2: Other MR imaging abnormalities associated with anti-LGI1 encephalitis
Studies (No.) Total Subjects (No.) Proportion
Amygdala T2 hyperintensity 3 94 9 (10%)
Insula T2 hyperintensity 5 153 12 (8%)
Cortical T2 FLAIR hyperintensity^a 4 79 14 (18%)
Cortical with diffusion restriction^a 3 85 2 (2%)
Leptomeningeal gadolinium enhancement 2 61 3 (5%)
MTL swelling 4 117 18 (15%)
MTL atrophy^{^b} 7 353 55 (16%)
MTL with gadolinium enhancement 2 151 5 (3%)
MTL atrophy or mesial temporal sclerosis on follow-up 6 154 71 (46%)
BG atrophy 2 102 3 (3%)
a Excluding MTL and insula.
↵b The time of the MR imaging relative to symptom initiation was not available.

	Studies (No.)	Total Subjects (No.)	Proportion
Amygdala T2 hyperintensity	3	94	9 (10%)
Insula T2 hyperintensity	5	153	12 (8%)
Cortical T2 FLAIR hyperintensity^a	4	79	14 (18%)
Cortical with diffusion restriction^a	3	85	2 (2%)
Leptomeningeal gadolinium enhancement	2	61	3 (5%)
MTL swelling	4	117	18 (15%)
MTL atrophy^{^b}	7	353	55 (16%)
MTL with gadolinium enhancement	2	151	5 (3%)
MTL atrophy or mesial temporal sclerosis on follow-up	6	154	71 (46%)
BG atrophy	2	102	3 (3%)